Horseradish peroxidase-conjugated anti-mouse (Cat# 7076, RRID:AB_330924) and anti-rabbit antibodies (Cat# 7074, RRID:AB_2099233) were purchased from Cell Signaling Technology

Horseradish peroxidase-conjugated anti-mouse (Cat# 7076, RRID:AB_330924) and anti-rabbit antibodies (Cat# 7074, RRID:AB_2099233) were purchased from Cell Signaling Technology. == Findings == Compared to pertuzumab, 5G9 exhibited more potent synergistic cell growth inhibitory activity when combined with trastuzumab (85%vs. 55%,P<0.001). In addition, 5G9 exhibited a higher internalization rate than pertuzumab (20%vs. 9%,P<0.05), and was able to further synergize with trastuzumab to promote antigen-antibody endocytosis. The internalization rate of the combination of 5G9 and trastuzumab was higher than that of pertuzumab and trastuzumab (35%vs. 14%,P<0.001).In vivoanimal studies demonstrated that 5G9 in combination with trastuzumab showed more potent synergistic antitumor efficacy than the combination of pertuzumab and trastuzumab. == Interpretation == 5G9, together with trastuzumab, may provide a potential opportunity for more efficacious treatment of HER2-positive cancers. == Funding == National Natural Science Foundation of China; State Key Laboratory of Analytical Chemistry for Life Science. Keywords:Large-scale screening, 5G9, Trastuzumab, Pertuzumab, Synergistic efficacy Abbreviations:TRA, trastuzumab; PER, pertuzumab; TV, tumor volume; TGI, tumor growth inhibition == Research in context. == == Evidence before this study == The discovery of HER2-targeting monoclonal antibodies has revolutionized the treatment of HER2-positive cancers. Trastuzumab and pertuzumab are two monoclonal antibodies targeting HER2, and the combination use of trastuzumab and pertuzumab has been used as the first-line treatment for HER2 positive cancers. Because pertuzumab was primarily developed as HER2 dimerization inhibitor, and later was incidentally found to have synergistic activity with trastuzumab, it remains to know whether an optimal synergistic partner could be identified for maximizing the efficacy of trastuzumab. == Added value of this study == Here we recognized trastuzumab optimal synergistic antibodies (4H2, 4C9, 4G6, 5F12 and 5G9) by large level trastuzumab-based synergistic efficacy screening. These monoclonal antibodies bound to a unique epitope and showed comparable physiochemical properties, cell-based bioactivities andin vivoefficacy when combining with trastuzumab. 5G9 (a representative of LDE225 (NVP-LDE225, Sonidegib) these antibodies) -medicated HER2 endocytosis was significantly higher than either trastuzumab- or pertuzumab- medicated endocytosis. Unlike pertuzumab, 5G9 greatly enhanced trastuzumab-medicated HER2 endocytosis, consequently resulting in the degradation of HER2 protein, the disruption of HER2-medicated cell signaling pathway, and the initiation of apoptosis. Although only showing marginal antitumor efficacy of itself, 5G9 was able to greatly promote the antitumor efficacy of trastuzumab in bothin vitrobioassays andin vivoanimal models, and such combinational efficacy was due to synergistic effect, rather than addition effect. == Implications of all the available evidence == Our findings of 5G9 and its optimal synergistic efficacy with trastuzumab are of great significance in anti-HER2 therapy. To our knowledge, this is the first report for discovering novel antibody drug candidates by using a blockbuster drug-based large-scale synergistic functional screening. Alt-text: Unlabelled box == 1. Introduction == Human epithelial growth factor receptor-2 (HER2) is usually a receptor tyrosine kinase and a member of the transmembrane epithelial growth factor receptor (EGFR) family, which comprises EGFR (HER1), ErbB2 (HER2), HER3 and HER4 (1,2). HER2 is able to dimerize with itself or with other EGFR family members, thus activating downstream transmission transduction pathways of tyrosine phosphorylation, and eventually resulting in the regulation of various cellular functions, including cell proliferation, differentiation, and apoptosis ([3],[4],[5]). HER2 is usually moderately expressed in normal adult tissues, where it regulates cell growth and differentiation. As a key gene of cell survival, HER2 LDE225 (NVP-LDE225, Sonidegib) LDE225 (NVP-LDE225, Sonidegib) gene amplification and overexpression of the HER2 protein have Rabbit polyclonal to Caspase 8.This gene encodes a protein that is a member of the cysteine-aspartic acid protease (caspase) family.Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. LDE225 (NVP-LDE225, Sonidegib) been reported in 20%30% of breast cancer, gastric LDE225 (NVP-LDE225, Sonidegib) malignancy and ovarian malignancy cases, and correlate with greater metastatic potential and poor prognosis ([6],[7],[8]). Since its expression levels are relatively low in normal tissues, HER2 is an attractive target for targeted therapy (9,10). Anti-HER2 monoclonal antibodies were able to inhibit HER2 activity in some high expression tissues, which revolutionized the therapy of HER2-positive breast cancer patients, both in the early phase and the metastatic phase (11). To date, trastuzumab, pertuzumab and ado-trastuzumab-emtansine (T-DM1) have been approved for clinical use by the U.S. Food and Drug.